BRIEF published on 04/18/2026 at 01:40, 5 months ago Medicure Announces Leadership Change Pharmaceuticals Strategic Priorities Medicure Inc. Leadership Change United States Market
PRESS RELEASE published on 04/18/2026 at 01:35, 5 months ago Medicure Announces Resignation of President and Chief Operating Officer Medicure Inc. announces resignation of President and COO, Dr. Neil Owens. CEO Dr. Albert D. Friesen to assume responsibilities. Company remains focused on strategic priorities for the future Pharmaceuticals Resignation Healthcare Medicure Inc. Leadership
BRIEF published on 11/19/2025 at 23:05, 9 months 28 days ago Medicure's Q3 2025 Financial Results Reflect Revenue Growth Despite Net Loss Revenue Growth Marley Drug Net Loss AGGRASTAT® Sales Medicure Financial Results
PRESS RELEASE published on 11/19/2025 at 23:00, 9 months 28 days ago Medicure Reports Financial Results for Quarter Ended September 30, 2025 Medicure Inc. reports Q3 2025 results with total net revenue of $8.2 million, an overview of financial performance and key highlights Financial Performance Medicure Inc. Net Revenue Q3 2025 Results Highlights
BRIEF published on 11/13/2025 at 23:35, 10 months 4 days ago Medicure to Announce Q3 2025 Financial Results on November 20 Financial Results Conference Call Medicure Inc. U.S. Pharmaceuticals AGGRASTAT® And ZYPITAMAG®
PRESS RELEASE published on 11/13/2025 at 23:30, 10 months 4 days ago Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025 Medicure Inc. will present Financial Results for Q3 2025 on November 20, 2025, focusing on pharmaceutical development and commercialization in the U.S. market Financial Results Conference Call Pharmaceuticals Medicure Inc. Healthcare Products
BRIEF published on 08/20/2025 at 23:35, 1 year ago Medicure Reports Q2 2025 Financial Results Financial Results Net Loss Net Revenue Research Investment Pharmaceutical Business
PRESS RELEASE published on 08/20/2025 at 23:30, 1 year ago Medicure Reports Financial Results for Quarter Ended June 30, 2025 Medicure Inc. reports Q2 2025 financial results, including increased revenue from Marley Drug and ZYPITAMAG(R), and enhanced adjusted EBITDA. Find full details at www.medicure.com Financial Results Medicure Inc. Marley Drug ZYPITAMAG Q2 2025
BRIEF published on 08/18/2025 at 23:35, 1 year ago Medicure to Announce Q2 2025 Financial Results via Conference Call Financial Results Conference Call Pharmaceuticals Medicure Q2 2025
PRESS RELEASE published on 08/18/2025 at 23:30, 1 year ago Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025 Medicure Inc. to present Financial Results for Q2 2025 on August 21, 2025 via conference call. Operations and products focus detailed Financial Results Conference Call Pharmaceuticals Medicure Inc. Healthcare Products
Published on 09/18/2026 at 14:30, 5 hours 23 minutes ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 6 hours 23 minutes ago Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer
Published on 09/18/2026 at 06:30, 13 hours 23 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 18 hours 58 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 18:44, 1 hour 9 minutes ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 1 hour 40 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 1 hour 43 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 1 hour 46 minutes ago Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:34, 1 hour 19 minutes ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 1 day 2 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
